Skip to main content
. 2016 Nov 25;7(52):87232–87245. doi: 10.18632/oncotarget.13601

Figure 6. Co-treatment of forskolin, probenecid and rolipram leads to TNBC cell growth arrest.

Figure 6

(A) MDA-MB-231 and MDA-MB-436 cells were treated with 10μM forskolin, 500 μM probenecid and 3 μM rolipram alone or together for 4 days followed by MTT assay to determine cell growth. Data are means ± SD (n = 4). *P < 0.001 vs control. (B) MDA-MB-231 and MDA-MB-436 cells were co-treated with forskolin, probenecid and rolipram or left untreated for 1 day followed by flow cytometry to analyze cell cycle. (C) MDA-MB-231 and MDA-MB-436 cells were treated with the combination of forskolin, probenecid and rolipram or 5 mM 8-Br-cAMP or left untreated for 1 day, then lysed and cell lysates were subjected to western blotting to detect cyclin D1, cyclin E2, PCNA, p21, p27 and β-actin with the respective antibodies.